Felix Dietlein1,2, Carsten Kobe1, Melanie Hohberg1, Boris D Zlatopolskiy3, Philipp Krapf4, Heike Endepols1,3, Philipp Täger1, Jochen Hammes1, Axel Heidenreich5, Thorsten Persigehl6, Bernd Neumaier3,4, Alexander Drzezga1, Markus Dietlein7. 1. Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 3. Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany. 4. Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich, Germany. 5. Department of Urology, University Hospital of Cologne, Cologne, Germany; and. 6. Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Cologne, Germany. 7. Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany markus.dietlein@uk-koeln.de.
Abstract
18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver. We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA tracers. Methods: Among 668 patients, we selected 27 in whom PET/CT results obtained with 68Ga-PSMA-11, 18F-DCFPyL (2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid), or 18F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or negative or as oligometastatic disease (PET-1). Within 3 wk, a second PET scan with 18F-PSMA-1007 was performed (PET-2). The confidence in the interpretation of PSMA-positive locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2). Discordant PSMA-positive skeletal findings were examined by contrast-enhanced MRI. Results: For both readers, 18F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions. In PET-2, the clinical readout led to a significantly lower number of equivocal locoregional lesions (P = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (P = 0.023). Exclusively in PET-2, we observed a total of 15 PSMA-positive spots in the bone marrow of 6 patients (22%). None of the 15 discordant spots had a morphologic correlate on the corresponding CT scan or on the subsequent MRI scan. Thus, 18F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (P = 0.0006). Conclusion: 18F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions.
18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver. We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA tracers. Methods: Among 668 patients, we selected 27 in whom PET/CT results obtained with 68Ga-PSMA-11, 18F-DCFPyL (2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid), or 18F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or negative or as oligometastatic disease (PET-1). Within 3 wk, a second PET scan with 18F-PSMA-1007 was performed (PET-2). The confidence in the interpretation of PSMA-positive locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2). Discordant PSMA-positive skeletal findings were examined by contrast-enhanced MRI. Results: For both readers, 18F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions. In PET-2, the clinical readout led to a significantly lower number of equivocal locoregional lesions (P = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (P = 0.023). Exclusively in PET-2, we observed a total of 15 PSMA-positive spots in the bone marrow of 6 patients (22%). None of the 15 discordant spots had a morphologic correlate on the corresponding CT scan or on the subsequent MRI scan. Thus, 18F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (P = 0.0006). Conclusion: 18F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions.
Authors: Niloefar Ahmadi Bidakhvidi; Annouschka Laenen; Sander Jentjens; Christophe M Deroose; Koen Van Laere; Liesbeth De Wever; Cindy Mai; Charlien Berghen; Gert De Meerleer; Karin Haustermans; Steven Joniau; Wouter Everaerts; Karolien Goffin Journal: EJNMMI Res Date: 2021-04-30 Impact factor: 3.138
Authors: Falk Gühne; Stefanie Radke; Thomas Winkens; Christian Kühnel; Julia Greiser; Philipp Seifert; Robert Drescher; Martin Freesmeyer Journal: Pharmaceuticals (Basel) Date: 2021-12-22
Authors: Manuela A Hoffmann; Finn Edler von Eyben; Nicolas Fischer; Florian Rosar; Jonas Müller-Hübenthal; Hans-Georg Buchholz; Helmut J Wieler; Mathias Schreckenberger Journal: Cancers (Basel) Date: 2022-03-14 Impact factor: 6.639